|
While prostate cancer is second to skin
cancer as the most common form of cancer among American men, highly effective
treatment options can help foil the disease if it is detected early. "Treatment
depends on several factors, including the age and health of the patient, the stage
of the cancer and whether it has spread to other organs," says urologist
Jules Geltzeiler, M.D. "After weighing these factors, the medical team works
with each patient to develop an individualized treatment plan that best suits
his needs and gets him on the road to recovery." At
Monmouth Medical Center, the region's most comprehensive prostate management program
offers free lecture, screenings and a monthly support group to help men with prostate
cancer "learn to cope through knowledge and hope."
On the cutting
edge
Monmouth Medical Center offers a full range of urological
services, delivered by board-certified urologists with experience in the most
advanced treatments. In recent years, they have gained
extensive training in laparoscopic and other minimally invasive techniques, which
continue to revolutionize surgery for kidney stones, prostate disorders and various
forms of cancer. In 1998, the hospital was the first in
the region to introduce temporary high-dose-rate brachytherapy for the treatment
of intermediate and high-risk prostate cancer. For this effort, led by chief of
urology Arnold Grebler, M.D., and Adam Raben, M.D., chairman of the Institute
of Advanced Radiation Oncology, Monmouth won a Gallo Award for excellence in cancer
research from The Cancer Institute of New Jersey and the New Jersey State Commission
on Cancer Research.
 Monmouth's
team includes chief of urology Arnold Grabler,
M.D., in foreground, along with urologists,
from left, Samuel Litvin, M.D.; Jules Geltzeiler,
M.D.; and Ira Keselman, M.D.
| |
For a referral to
a Monmouth Medical Center urologist, call Med-Search at 732-870-5500.
FAVORABLE FOLLOW-UPS
"Evaluating the implant by CT (computed tomography)
scan one month after the procedure, we've been delighted
to find that the dose goals have been maintained,"
says Dr. Raben. "In our first year with this system,
we've been amazed at the lack of urinary and rectal symptoms
in our patients. It's very encouraging."
[ top
] |
